2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Genetic Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

5252 Spatial transcriptomic profiling of golcadomide-treated non-Hodgkin lymphoma reveals coordinated malignant B-cell reduction and localized immune remodeling

Wei Zhang, PhD, Oscar Echeagaray, PhD2, Jessica Voetsch, PhD3, Yan Kai, PhD4, Yulong Bai, PhD5, Michael Mason, PhD6, Julio Chavez, MD7, Jean-Marie Michot, MD8, Michael Pourdehnad, MD9, Celia Fontanillo, PhD10, Romain Georges, PhD11, Alberto Risueño12, Soraya Carrancio, PhD13
1 Bristol Myers Squibb, San Diego, California, United States
2 Bristol Myers Squibb, San Diego, California, United States
3 Bristol Myers Squibb, Lawrenceville, New Jersey, United States
4 Bristol Myers Squibb, San Diego, California, United States
5 Bristol Myers Squibb, Cambridge, Massachusetts, United States
6 Bristol Myers Squibb, Seattle, Washington, United States
7 Mayo Clinic, Jacksonville, Florida, United States
8 Institut Gustave Roussy, Villejuif, France
9 Bristol Myers Squibb, Brisbane, California, United States
10 Bristol Myers Squibb, San Diego, California, United States
11 Bristol Myers Squibb, San Diego, California, United States
12 Bristol Myers Squibb, Lawrenceville, New Jersey, United States
13 Bristol Myers Squibb, San Diego, California, United States

Golcadomide (Golca, CC-99282) is an investigational oral cereblon-modulating agent (CELMoD) in clinical development for non-Hodgkin lymphoma. Golcadomide induces degradation of Ikaros (IKZF1) and Aiolos (IKZF3), suppresses MYC- and IRF4-associated B-cell programs, activates interferon-stimulated genes, and promotes immune-stimulatory activity in preclinical lymphoma models. However, whether golcadomide-associated malignant B-cell reprogramming is spatially coupled to immune remodeling and tumor-cell clearance within patient tissue remains unknown. Because therapeutic response is shaped by regional tumor–immune architecture that bulk and dissociated single-cell assays cannot resolve, we applied high-resolution spatial transcriptomics to investigate golcadomide-associated tissue remodeling in situ.

We profiled paired screening and on-treatment (Cycle 1, Day 10–12) FFPE biopsies collected from 20 patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) enrolled in the first-in-human study CC-99282-NHL-001 (NCT03930953), using the 10x Genomics Xenium platform with a custom ~5,100-gene panel enriched for genes involved in golcadomide mechanism of action (MoA). The cohort spans three arms: DLBCL treated with golcadomide plus rituximab, DLBCL treated with golcadomide monotherapy, and FL treated with golcadomide plus rituximab. Xenium profiling generated 19.4 million single-cell measurements, and full-cohort analyses are ongoing. Here, we report an interim analysis of six responders, resolving malignant B-cell states, T-cell subsets, NK cells, and myeloid populations between pre- and on-treatment tissue pairs. Complete cohort results will be presented at the congress.

Across all six responders with paired pre- and on-treatment biopsies, golcadomide treatment was associated with coordinated tumor and immune remodeling. Malignant B-cell fractions decreased from ~34-60% at screening to ~7-21% of profiled cells on treatment, accompanied by expansion of CD8+ T cells from ~2-21% to ~18-45% and CD163+ macrophages from ~1-4% to ~10-19%. NK-cell enrichment was also observed in a subset of patients. Within malignant B cells, gene-signature analysis demonstrated transcriptional reprogramming characterized by modulation of IKZF1/3-regulated programs, activation of interferon-stimulated gene signatures, attenuation of proliferative programs, and increased apoptotic signaling, consistent with engagement of the expected tumor-intrinsic MoA in patient tissue. Treatment-associated remodeling was spatially organized but heterogeneous: on-treatment biopsies contained T-cell–enriched regions interleaved with residual malignant B-cell–dense niches, revealing spatial heterogeneity in early treatment-associated remodeling that would not be resolved by bulk or dissociated single-cell profiling.

Together, these interim data provide early in situ evidence that golcadomide treatment is associated with coordinated malignant B-cell reprogramming and reduction, together with spatially organized remodeling of the lymphoma immune microenvironment. The coexistence of immune-enriched regions and residual malignant B-cell–dense niches highlights spatial heterogeneity during early treatment-associated remodeling. Full-cohort analyses will evaluate whether these niches differ between responders and non-responders, represent distinct tumor–immune neighborhoods, or are associated with specific molecular programs. Overall, these findings support broad activity of golcadomide across NHL and provide a spatially resolved rationale for combining it with anti-lymphoma agents directed against malignant B cells and/or the tumor microenvironment.

Wei Zhang, PhD: Bristol Myers Squibb - Current equity holder in publicly-traded company; Bristol Myers Squibb - Current Employment